Relation between waist circumference and MAFLD (metabolic associated fatty liver disease) in Hypertensive Patients.
Sayed, W., Attia, D., Boshra, H., Nafady, S. (2025). Relation between waist circumference and MAFLD (metabolic associated fatty liver disease) in Hypertensive Patients.. EKB Journal Management System, 6(3), 181-192. doi: 10.21608/ejmr.2023.188103.1323
Walaa Mohamed Sayed; Dina Ismail Attia; Hesham Boshra; Shaymaa Nafady. "Relation between waist circumference and MAFLD (metabolic associated fatty liver disease) in Hypertensive Patients.". EKB Journal Management System, 6, 3, 2025, 181-192. doi: 10.21608/ejmr.2023.188103.1323
Sayed, W., Attia, D., Boshra, H., Nafady, S. (2025). 'Relation between waist circumference and MAFLD (metabolic associated fatty liver disease) in Hypertensive Patients.', EKB Journal Management System, 6(3), pp. 181-192. doi: 10.21608/ejmr.2023.188103.1323
Sayed, W., Attia, D., Boshra, H., Nafady, S. Relation between waist circumference and MAFLD (metabolic associated fatty liver disease) in Hypertensive Patients.. EKB Journal Management System, 2025; 6(3): 181-192. doi: 10.21608/ejmr.2023.188103.1323

Relation between waist circumference and MAFLD (metabolic associated fatty liver disease) in Hypertensive Patients.

Egyptian Journal of Medical Research
Volume 6, Issue 3, July 2025, Page 181-192  XML PDF (479.8 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2023.188103.1323
View on SCiNiTO View on SCiNiTO
Authors
Walaa Mohamed Sayed email 1; Dina Ismail Attia1; Hesham Boshra2; Shaymaa Nafady1
1Tropical Medicine department, Faculty of Medicine, Beni-Suef University.
2Cardiology department, Faculty of Medicine, Beni-Suef University.
Abstract
Objective: Finding the relation between waist circumference and metabolic associated fatty liver disease (MAFLD) in Hypertensive patients. Patients and Methods: Two hundred subjects were enrolled in our study. They were recruited from The Cardiology Department, Beni-Suef University Hospitals in the duration from February 2021 to July   2021 after obtaining an informed consent. Results: Prevalence of MAFLD among the hypertension population was high (68.5%). There was significant association between waist circumference and body mass index and development of metabolic associated fatty liver disease (MAFLD) in studied population as they increase prevalence of MAFLD. As regarding laboratory investigations only triglyceride was higher in MAFLD patients. Conclusion: The present study shows that Prevalence of MAFLD among the hypertensive population was high. Waist circumference was high in MAFLD patients. MAFLD is associated with higher level of triglyceride.
Keywords
MAFLD; Waist circumference; Hypertension; Metabolic syndrome; CVD
References
  1. Chalasani N, Younossi Z, Lavine J, et al (2018): The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Hepatol-ogy.; 67:328–357.
  2. Fouad Y, Waked I, Bollipo S, et al (2020): What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’, Liv Journal; 40: 1254-61.
  3. Choudhary N, Duseja A, Kalra N, et al (2018): Correlation of adipose tissue with liver histology in Asian Indian pa- tients with nonalcoholic fatty liver disease (NAFLD). Ann ; 11:478–486.
  4. Stepanova M, Rafiq N, Makhlouf H, et al (2013): Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis ; 58:3017-3023.
  5. Nigam P, Bhatt SP, Misra A, et al (2013): Non-alcoholic fatty liver disease is closely associated with sub- clinical inflammation: a case-control study on Asian Indians in North India. PLoS One.; 8(1) e49286.
  6. Fargion S, Porzio M, Fracanzani A (2014): Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J Gastroenterology.; 20:13306–13324.
  7. Berzigotti A, Bonfiglioli A, Muscari A, et al (2005): Reduced prevalence of ischemic events and abnormal supraortic flow patterns in patients with liver cirrhosis. Liver Int.; 25:331–336.
  8. Fouad, Y., Esmat, G., Elwakil, R., et al (2022): The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association, 28(1), 3.‏
  9. Golzarand M, Mirmiran P, Jessri M., et al (2012): Dietary trends in the Middle East and North Africa: An ecological study (1961 to 2007) Public Health Nutr.; 15:1835–414.
  10. Younossi Z, Tacke F, Arrese M., et al (2019): Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 69:2672–82.
  11. Abdel Alem S GY, AbdAlla M, Said E, et al (2021): Capturing patient experience: A qualitative study of change from NAFLD to MAFLD real-time feedback. J Hepatology; 74:1261–2.
  12. Alexander M, Loomis AK, Fairburn-Beech J, et al (2018): Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med.; 16:1–11. Doi: 10.1186/s12916-018-1103-x.
  13. Bertot LC, Jeffrey GP, Wallace M, et al (2017); Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma. Hepatol Commune.; 1:53–60.
  14. Lonardo, A., Nascimbeni, F., Mantovani, A., et al (2018): Hypertension, diabetes, atherosclerosis and NASH: cause or consequence. Journal of hepatology, 68(2), 335-352.‏
  15. Ajmal, M. R., Yaccha, M., Malik, M. A., et al (2014): Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-α. Indian heart journal, 66(6), 574-579.‏
  16. Lin S, Huang J, Wang M, et al (2020): Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int.
  17. Donati, G., Stagni, B., Piscaglia, F., et al (2004): Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut, 53(7), 1020-1023.‏
  18. Aneni, E. C., Oni, E. T., Martin, S. S., et al (2015): Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardio metabolic risk. Journal of hypertension, 33(6), 1207-1214.‏
  19. Targher, G., Corey, K. E., Byrne, C. D., et al (2021): The complex link between NAFLD and type 2 diabetes mellitus—mechanisms and treatments. Nature reviews Gastroenterology & hepatology, 18(9), 599-612.‏
  20. Targher, G., Bertolini, L., Padovani, R., et al (2007): Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes care, 30(5), 1212-1218.
  21. Church, T. S., Kuk, J. L., Ross, R., et al (2006): Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology, 130(7), 2023-2030.‏
  22. Rocha, R., Cotrim, H. P., Carvalho, F. M., et al (2005): Body mass index and waist circumference in non‐alcoholic fatty liver disease. Journal of human nutrition and dietetics, 18(5), 365-370.‏
  23. Alves-Bezerra, M., & Cohen, D. E. (2017): Triglyceride metabolism in the liver. Comprehensive Physiology, 8(1), 1.‏
  24. Gorden, D. L., et al (2015): Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J. Lipid Res. 56, 722–736.
  25. McPherson, S., Hardy, T., Dufour, J. F., et al (2017): Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. The American journal of gastroenterology, 112(5), 740.‏
Statistics
Article View: 9
PDF Download: 5